Literature DB >> 27293842

Long term complications following 54 consecutive lung transplants.

Walther Tabarelli1, Hugo Bonatti1, Dominique Tabarelli1, Miriam Eller1, Ludwig Müller1, Elfriede Ruttmann1, Cornelia Lass-Flörl1, Clara Larcher1, Christian Geltner1.   

Abstract

BACKGROUND: Due to the complex therapy and the required high level of immunosuppression, lung recipients are at high risk to develop many different long term complications.
METHODS: From 1993-2000, a total of 54 lung transplantation (LuTx) were performed at our center. Complications, graft and patient survival of this cohort was retrospectively analyzed.
RESULTS: One/five and ten-year patient survival was 71.4%, 41.2% and 25.4%; at last follow up (4/2010), twelve patients were alive. Of the 39 deceased patients, 26 died from infectious complications. Other causes of death were myocardial infarction (n=1), progressive graft failure (n=1), intracerebral bleeding (n=2), basilary vein thrombosis (n=1), pulmonary emboli (n=1), others (n=7). Surgical complication rate was 27.7% during the first year and 25% for the 12 long term survivors. Perioperative rejection rate was 35%, and 91.6% for the 12 patients currently alive. Infection incidence during first hospitalization was 79.6% (1.3 episodes per transplant) and 100% for long term survivors. Commonly isolated pathogens were cytomegalovirus (56.8%), Aspergillus (29.4%), RSV (13.7%). Other common complications were renal failure (56.8%), osteoporosis (54.9%), hypertension (45%), diabetes mellitus (19.6%).
CONCLUSIONS: Infection and rejection remain the most common complications following LuTx with many other events to be considered.

Entities:  

Keywords:  Lung transplantation (LuTx); complications; cytomegalovirus; long term; outcome

Year:  2016        PMID: 27293842      PMCID: PMC4885970          DOI: 10.21037/jtd.2016.05.03

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  52 in total

1.  Managing complications following lung transplantation.

Authors:  Isabel P Neuringer; Peadar Noone; Rebecca K Cicale; Ken Davis; Robert M Aris
Journal:  Expert Rev Respir Med       Date:  2009-08       Impact factor: 3.772

Review 2.  Current trends in immunosuppression for lung transplantation.

Authors:  Timothy Floreth; Sangeeta M Bhorade
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

Review 3.  Viral infections in lung transplant recipients.

Authors:  Pali Dedhiya Shah; John F McDyer
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

4.  Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report--2008.

Authors:  Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2008-09       Impact factor: 10.247

5.  Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.

Authors:  Elfriede Ruttmann; Christian Geltner; Brigitte Bucher; Hanno Ulmer; Daniel Höfer; Herbert B Hangler; Severin Semsroth; Raimund Margreiter; Günther Laufer; Ludwig C Müller
Journal:  Transplantation       Date:  2006-05-27       Impact factor: 4.939

Review 6.  Infectious complications of lung transplantation.

Authors:  B D Alexander; V F Tapson
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

7.  Nocardia infection in lung transplant recipients.

Authors:  Shahid Husain; Kenneth McCurry; James Dauber; Nina Singh; Shimon Kusne
Journal:  J Heart Lung Transplant       Date:  2002-03       Impact factor: 10.247

8.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.

Authors:  Glen P Westall; Alexandra Michaelides; Trevor J Williams; Greg I Snell; Thomas C Kotsimbos
Journal:  Transplantation       Date:  2003-06-27       Impact factor: 4.939

10.  Development of neoplasms during lung transplantation follow-up.

Authors:  M Delgado; R Fernández; M Paradela; M De La Torre; D González; J A García; J M Borro
Journal:  Transplant Proc       Date:  2008-11       Impact factor: 1.066

View more
  3 in total

1.  What is the role of empirical treatment for suspected invasive candidiasis in non-neutropenic non transplanted patients in the intensive care unit?-Empiricus strikes back!

Authors:  Cédric Bretonnière; Karim Lakhal; Thierry Lepoivre; David Boutoille; Florent Morio
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Heparin-binding protein, lysozyme, and inflammatory cytokines in bronchoalveolar lavage fluid as diagnostic tools for pulmonary infection in lung transplanted patients.

Authors:  Anna Stjärne Aspelund; Helena Hammarström; Malin Inghammar; Hillevi Larsson; Lennart Hansson; Bertil Christensson; Lisa I Påhlman
Journal:  Am J Transplant       Date:  2017-09-15       Impact factor: 8.086

Review 3.  A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses.

Authors:  Emily S Bailey; Juliana N Zemke; Jessica Y Choi; Gregory C Gray
Journal:  Front Immunol       Date:  2019-12-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.